Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their ?15mln funding aimed at accelerating the development of its two lead products.
Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment for Acute Respiratory Distress Syndrome (ARDS).
Results from a phase III trial (INTEREST) are expected early in the spring, but Faron's keen to lay the groundwork for a product launch.
The money will also enable Faron to expand the scope of the upcoming phase I/IIb trial of immunotherapy cancer treatment Clevegen.
Meet Medusa Mining, Cora Gold, Group Eleven Resources Ltd., Harvest Minerals Ltd. and Crusader Resources Ltd at our event, London, 22 February 2018.Register here >>